Molecular determinants of angiogenesis in cancer metastasis

Cancer Journal from Scientific American

Volumn 4, Issue SUPPL. 1, 1998, Pages

  Fidler, Isaiah J ^a   Kumar, Rakesh ^a   Bielenberg, Diane R ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ARTICLE; HEMANGIOMA; HUMAN; LYMPHOID CELL; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0031866049     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (133)

1. Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer 979;3:1-59.
2. Weiss L. Principles of Metastasis. Orlando, Florida: Academic Press, 1985.
3. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res 1990;50:6130-6138.
4. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995;87:1588-1592.
5. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980;283:139-146.
6. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim Biophys Acta 1989;989:65-87.
7. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995;1:27-31.
9. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1753-1763.
10. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994;63:265-311.
11. Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235: 444-447.
12. Gabbert H. Mechanisms of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev 1985;4:293-310.
13. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation (review). Cancer Res 1991;51:5054s-5059s.
14. Sloane B, Honn KV. Cysteine proteinase and metastasis. Cancer Metastasis Rev 1984;3:249-265.
15. Fidler IJ, Kripke ML. Tumor cell antigenicity, host immunity and cancer metastasis. Cancer Immunol Immunother 1980;7:201-205.
16. Price JE, Aukerman SL, Fidler IJ. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 1986;46:5172-5178.
17. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451-2460.
18. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Im Rev Cytol 1995;159:113-160.
19. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
20. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174.
21. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1753-1763.
22. Shing Y, Folkman J, Haudenschild C et al. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 1985;29:275-287.
23. Leung ZW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
24. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-1478.
25. Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
26. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
27. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
28. Ishikawa F, Miyazone K, Hellman U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-562.
29. Bussolino F, DiRenzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-641.
30. Rosen EM, Grant DS, Kleinman HK et al. Scatter factor (hepatocyte growth factor) is a potent angiogenic factor in vivo. Symp Soc Exp Biol 1993;47:227-234.
31. Heldin C-H. Structural and functional studies on platelet-derived growth factor. EMBO J 1992;11:4251-4259.
32. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
33. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
34. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: Lippincott-Raven, 1996:167-190.
35. Gasparini G, Fox SB, Verderio P et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996;2:1191-1198.
36. Ellis LM, Fidler IJ. Angiogenesis and breast cancer metastasis. Lancet 1995;346:388-389.
37. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 1976;192:1237-1238.
38. Fidler IJ, Gersten DM, Kripke ML. Influence of immune status on the metastasis of diree murine fibrosarcomas of different immunogenicities. Cancer Res 1979;39:3816-3821.
39. Fidler IJ. Lymphocytes are not only immunocytes (guest editorial). Biomedicine 1980;32:1-3.
40. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992;3:73-79.
41. Miguez M, Davel L, de Lustig ES. Lymphocyte-induced angiogenesis: correlation with the metastatic incidence of two murine mammary adenocarcinomas. Invasion Metastasis 1986;6:313-320.
42. Freeman MR, Schneck FX, Gagnon ML et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55:4140-4145.
43. Polverini P, Cotran R, Gimbrone N et al. Activated macrophages induce vascular proliferation. Nature 1977;269:804-805.
44. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.
45. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994;56:423-435.
46. Takahashi Y, Bucana CD, Liu W et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996;88:1146-1151.
47. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 1993;143: 678-684.
48. Rappolee DA, Mark D, Banda MJ et al. Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping. Science 1988;241:708-712.
49. Fidler IJ, Gersten DM. Effect of syngeneic lymphocytes on the vascularity, growth, and induced metastasis of the B16 melanoma. In: Crispen R, ed. Neoplasm Immunity: Experimental and Clinical. New York: Elsevier/North Holland Publishing Co, 1980:3-15.
50. Gutman M, Singh RK, Yoon S et al. Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. Cancer Biother 1994;9:163-170.
51. Smolle J, Soyer HP, Hoffman-Wellenhof R et al. Vascular architecture of melanocytic skin tumors. Pathol Res Pract 1989;185: 740-745.
52. Brocker EG, Rechenbeld C, Hamm H et al. Macrophages in melanocytic naevi. Arch Dermatol Res 1992;284:127-131.
53. Klausner JM, Gutman M, Inbar M et al. Unknown primary melanoma. J Surg Oncol 1983;24:129-131.
54. Ruiter DJ, Bhan AK, Harris TJ et al. Major histocompatibility antigens and the mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J Immunol 1982;129:2808-2815.
55. Sunderkotter C, Goebeler M, Schultze-Osthoff K et al. Macrophage-derived angiogenic factors. Pharmacol Ther 1991;51:195-216.
56. Polverini JJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial cell proliferation in vitro by tumor-associated macrophages. Lab Invest 1984;51:635-642.
57. Polverini PJ. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Cancer 1996; 32A:2430-2437.
58. Ingber D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 1991;47: 236-241.
59. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989;58:803-805.
60. Lingen MW, Polverini PJ, Bouck N. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996;74:476-483.
61. Lingen MW, Polverini PJ, Bouck N. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become antiangiogenic. Am J Pathol 1996;149:247-258.
62. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
63. Dong Z, Kumar R, Yang X et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
64. Kumar R, Dong Z, Fidler IJ. Differential regulation of metalloelastase activity in murine peritoneal macrophages by GM-CSF and M-CSF. J Immunol 1996;157:5104-5111.
65. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-573.
66. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origin and implications. Science 1982;217:998-1003.
67. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-895.
68. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastasis. Science 1982;217:361-363.
69. Fidler IJ, Talmadge JE. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 1986;46:5167-5171.
70. Fidler IJ. Experimental orthotopic models of organ-specific metastasis by human neoplasms. Adv Mol Cell Biol 1994;9:191-215.
71. Hart IR. "Seed and soil" revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev 1982;1:5-7.
72. Tarin D, Price JE, Kettlewell MGW et al. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Br Med J 1984;288:749-751.
73. Tarin D, Price JE, Kettlewell MGW et al. Mechanism of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984;44:3584-3592.
74. Nanus DM, Schmitz-Drager BJ, Motzer RJ et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Nad Cancer Inst 1994;85:1597-1599.
75. Naito S, von Eschenbach AC, Giavazzi R et al. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 1986;46: 4109-4115.
76. Singh RK, Bucana CD, Gutman M et al. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994;145:365-374.
77. Singh RK, Gutman M, Bucana CD et al. Interferon-α and -β downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Nad Acad Sci USA 1995;92:45624566.
78. Singh RK, Gutman M, Radinsky R et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994;54:3242-3247.
79. Gutman M, Singh RK, Xie K et al. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 1995;55:2470-2475.
80. Takahashi Y, Mai M, Wilson MR et al. Site-dependent expression of vascular endothelial growth factor, angiogenesis, and proliferation in human gastric carcinoma. Int J Oncol 1996;8:701-705.
81. Fidler IJ, Ellis LM. The implication of angiogenesis to the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
82. Dameron KM, Volpert OV, Tanisky MA et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1502-1504.
83. Hanahan D, Christofori G, Naik P et al. Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A:2386-2393.
84. Singh RK, Llansa N, Bucana CD et al. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differen 1996;7:397-404.
85. Koura AN, Liu W, Kitadai Y et al. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 1996;56:3891-3894.
86. Kitadai Y, Ellis LM, Takahashi Y et al. Multiparametric in situ mRNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinoma. Clin Cancer Res 1995;1:1095-1102.
87. Kitadai Y, Ellis LM, Tucker SL et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in padents with colon carcinoma. Am J Pathol 1996;149:1541-1551.
88. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
89. Ricketts RR, Hadey RM, Corden BJ et al. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 1994;6:605-614.
90. Ohlms LA, McGill TJI, Jones DT et al. Interferon-alfa-2A therapy for airway hemangiomas. Ann Otol Rhinol Laryngol 1994; 103:1-8.
91. Soumekh B, Adams GL, Shapiro RS. Treatment of head and neck hemangiomas with recombinant interferon-alpha-2b. Ann Otol Rhinol Laryngol 1996;105:201-206.
92. Orchard PJ, Smith CM, Woods WG et al. Treatment of haemangioendotheliomas with alpha Interferon. Lancet 1989;2:565-567.
93. White CW, Sondheimer HM, Crouch EC et al. Treatment of pulmonary hemangiomatosis with recombinant interferon-alfa-2a. N Engl J Med 1989;320:1197-200.
94. Kim DH, Kramer A. Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Nad Cancer Inst 1996;88:764-765.
95. Groopman JE, Gottlieb MS, Goodman J et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:671-676.
96. Singh RK, Gutman M, Llansa N et al. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells. J Interferon Cytokine Res 1996;16:577-584.
97. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-4735.
98. Brown LF, Berse B, Jackman RW et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-1262.
99. Shweiki D, Itin A, Stoffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
100. Ikeda E, Achen MG, Breier G et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;34: 19761-19768.
101. Levy AP, Levy NS, Wegner S et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-13340.
102. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated in response to growth factors in human glioma cells. Oncol Rep 1995;2:1059-1061.
103. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995;358:311-315.
104. Cohen T, Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-741.
105. Li J, Perrella MA, Tsai JC et al. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem 1995;270:308-312.
106. Pertovaara L, Kaipainen A, Mustonen T et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994; 269:6271-6274.
107. Mukhopadhyay D, Tsiokas L, Zhou XM et al. Hypoxic induction of human vascular endothelial growth factor expression through c-src activation. Nature 1995;375:577-581.
108. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580.
109. Rak J, Filmus J, Finkenzeller G et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-277.
110. Mukhopadhyay D, Tsiokas L, Sukhatme W. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-6165.
111. Folkman J, Mulliken JB, Ezekowitz RAB. Antiangiogenic therapy of hemangiomas with interferon-alpha. In: Stuart-Harris R, Penny R, eds. Clinical Applications of the Interferons. London: Chapman & Hall, 1997:255-265.
112. Enjolras O, Riché MC, Merland JJ et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990;5:491-498.
113. Issacs A, Lindenmann J. Virus interference: I. The Interferon. Proc R Soc Ser B 1957;147:258-267.
114. Thomas H, Balkwill FR. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 1991;52: 307-330.
115. Tamm I, Lin SL, Pfeiffer LM et al. Interferons α and β as cellular regulatory molecules. In: Gresser I, ed. Interferon 9. London: Academic Press, 1987;14-73.
116. Resnitzky D, Yarden A, Zipori D et al. Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation. Cell 1986;46:31-40.
117. Sinkovics JG. Interferons: antiangiogenesis agents (a reasonable theory). Can J Infect Diseases 1992;3:128B-132B.
118. Heyns A, Eldor A, Vlodavsky I et al. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Exp Cell Res 1985;161:297-306.
119. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by γ-interferon. J Cell Biol 1987;104:689-696.
120. Ruszczak Z, Detmar M, Imcke E et al. Effects of rIFN-α, -β, and -γ on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 1990;95:693-699.
121. Hicks C, Penny R. Response of microvascular endothelial cells to biological response modifiers. Immunol Cell Biol 1989;67:271-277.
122. Brouty-Boye D, Zetter BR Inhibition of cell motility by interferon. Science 1980;208:516-518.
123. Fukuzawa K, Horikoshi T. Inhibitory effect of human fibro-blast interferon (HuIFN-β) on the growth and invasive potential of cultured human melanoma cells in vitro. Br J Dermatol 1992;126: 324-330.
124. Stout AJ, Gresser I, Thompson WD. Inhibition of wound healing in mice by local interferon α/β injection. Int J Exp Pathol 1993;74:79-85.
125. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497-502.
126. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5561.
127. Oliveira IC, Sciavolino PJ, Lee TH et al. Downregulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 1992;89:9049-9053.
128. Van Damme J, Opdenakker G. Interaction of interferons with skin reactive cytokines: from interleukin-1 to interleukin-8. J Invest Dermatol 1990;95:905-35.
129. Singh RK, Bucana CD, Llansa N et al. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int J Oncol 1996;8:649-656.
130. Fabra A, Nakajima M, Bucana CD et al. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 1992;52:101-110.
131. Gohji K, Fidler IJ, Tsan R et al. Human recombinant interferons β and γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int J Cancer 1994;58:380-384.
132. Kato N, Nawa A, Tamakoshi K et al. Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-beta. Am J Obstet Gynecol 1995;172:601-606.
133. Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 1985;12:207-221.